News
LPCN
5.51
-5.33%
-0.31
Weekly Report: what happened at LPCN last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at LPCN last week (0708-0712)?
Weekly Report · 07/15 09:34
Weekly Report: what happened at LPCN last week (0701-0705)?
Weekly Report · 07/08 09:35
Weekly Report: what happened at LPCN last week (0624-0628)?
Weekly Report · 07/01 09:35
LIPOCINE INC: LPCN 1154 WAS WELL TOLERATED WITH NO SEDATION OR SOMNOLENCE EVENTS OBSERVED
Reuters · 06/25 12:07
Lipocine Says LPCN 1154 Met standard Bioequivalence (BE) Criteria; Co Says On Track For NDA Filing, Targeting Q4 2024
Benzinga · 06/25 12:06
Weekly Report: what happened at LPCN last week (0617-0621)?
Weekly Report · 06/24 09:37
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 06/19 16:30
Weekly Report: what happened at LPCN last week (0610-0614)?
Weekly Report · 06/17 09:34
Lipocine To Present 52 Week Results From LPCN 1148 Phase 2 Study In Late Breaking Session At EASL Congress 2024
Phase 2 results on LPCN 1148 in cirrhosis featured in oral presentation at the European Association for the Study of Liver (EASL) Congress in Milan, Italy. The presentation is featured in the symposium "Revolutionary Advances in Liver Disease Research"
Benzinga · 06/10 12:02
Weekly Report: what happened at LPCN last week (0603-0607)?
Weekly Report · 06/10 09:35
Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
NASDAQ · 06/06 12:50
Lipocine Sets Employee Bonuses and Expands Stock Plan
TipRanks · 06/03 21:52
Weekly Report: what happened at LPCN last week (0527-0531)?
Weekly Report · 06/03 09:36
Weekly Report: what happened at LPCN last week (0520-0524)?
Weekly Report · 05/27 09:37
Here's Why Momentum in Lipocine (LPCN) Should Keep going
NASDAQ · 05/21 12:50
Weekly Report: what happened at LPCN last week (0513-0517)?
Weekly Report · 05/20 09:36
Weekly Report: what happened at LPCN last week (0506-0510)?
Weekly Report · 05/13 09:38
LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024
Lipocine reported earnings per share of 66 cents for the first quarter of 2024. The company reported revenue of $7.62 million. Lipocine's results were above the analyst estimate for EPS of -68 cents. The stock is up 2% today.
Investorplace · 05/09 17:53
Lipocine GAAP EPS of $0.66, revenue of $7.62M
Seeking Alpha · 05/09 14:35
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor and LPCN 1148, a novel androgen receptor agonist prodrug for oral administration targeted for the management of symptoms associated with liver cirrhosis. It is exploring partnering opportunities for LPCN 1107, for prevention of preterm birth, LPCN1154, for rapid relief of postpartum depression, LPCN 1148, for the management of decompensated cirrhosis, and LPCN 1144, for treatment of non-cirrhotic NASH. Its product candidate, TLANDO, an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.